References on the Administration of Vascular Endothelial Factor Using ALZET^® Osmotic Pumps

Q0878 Ortuzar,N., Argandona,E.G., Bengoetxea,H., Lafuente,J.V. Combination of intracortically administered VEGF and environmental enrichment enhances brain protection in developing rats. Journal of Neural Transmission 2011; 118(-1-):135-144. >>> Vascular endothelial growth factor; CSF/CNS (cortex); Rat; 1007D; 7 days; Controls received mp w/ PBS or no implantation; animal info (Long-Evans, P18); cyanoacrylate adhesive; ALZET brain infusion kit 3 used; "Total operating time was approximately 25 min." pg 137.

Q0712 Nicoletti,J.N., Lenzer,J., Salerni,E.A., Shah,S.K., Elkady,A., Khalid,S., Quinteros,D., Rotella,F., Betancourth,D., Croll,S.D. Vascular endothelial growth factor attenuates status epilepticus-induced behavioral impairments in rats. EPILEPSY&BEHAVIOR 2010; 19(-3-):272-277. >>> Vascular endothelial growth factor, 165, recomb. human; vascular endothelial growth factor, inactivated; PBS, sterile; CSF/CNS (hippocampus); Rat; 2002; 2 weeks; Controls received no surgical manipulations or protein infusions; animal info (male Sprague-Dawley, 250-350 g); behavioral testing (Morris water maze, Grid locomotor activity, Light-dark exploration).

Q0514 Lee,C., Agoston,D.V. Inhibition of VEGF receptor 2 increased cell death of dentate hilar neurons after traumatic brain injury. Experimental Neurology 2009; 220(-2-):400-403. >>> Vascular endothelial growth factor (164); SU5416; CSF, artificial; DMSO; CSF/CNS; Rat; 1002; 13 days; Controls received mp w/ vehicle; animal info (young, male, Sprague Dawley, 270-330 g.); cannula placement verified by histology; 1% DMSO used; artificial CSF recipe.

Q0400 Bogaert,E., Van Damme,P., Poesen,K., Dhondt,J., Hersmus,N., Kiraly,D., Scheveneels,W., Robberecht,W., Van den Bosch,L. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. NEUROBIOLOGY OF AGING 2010; 31(-12-):2185-2191. >>> Vascular endothelial growth factor; CSF/CNS; Rat; 2004; 1 week; Controls received mp w/ vehicle; animal info (80 days old).

Q0354 Ahmed,A., Singh,J., Khan,Y., Seshan,S.V., Girardi,G. A New Mouse Model to Explore Therapies for Preeclampsia. PLoS One 2010; 5(-10-):U325-U333. >>> Vascular endothelial growth factor (121); PBS, sterile; SC; Mice; 7 days; Animal info (CBA/J x DBA/2 and CBA/J x BALB/c).

Q0282 Schmidt,C., Bezuidenhout,D., Beck,M., Van der Merwe,E., Zilla,P., Davies,N. Rapid three-dimensional quantification of VEGF-induced scaffold neovascularisation by microcomputed tomography. Biomaterials 2009; 30(-30-):5959-5968. >>> Vascular endothelial growth factor (165); SC; Rat; 1002; 10 days; Controls received mp w/ PBS; animal info (male, Wistar, 234-254 g); functionality of mp verified by residual volume; post op. care (buprenorphine); pump connected to a porous polyurethane construct, schematic on Figure 1A;.

P9814 Santulli,G., Ciccarelli,M., Palumbo,G., Campanile,A., Galasso,G., Ziaco,B., Altobelli,G.G., Cimini,V., Piscione,F., D'Andrea,L.D., Pedone,C., Trimarco,B., Iaccarino,G. In vivo properties of the proangiogenic peptide QK. Journal of Translational Medicine 2009; 7(-;-):U1-U10. >>> Vascular endothelial growth factor-15; vascular endothelial growth factor-165; QK; IA (femoral); Rat; 2002; 14 days; Peptides; animal info (12 wks old, WKY, normosensitive); QK is a de novo engineered VEGF mimicking peptide.

P9708 Schmidt,N.O., Koeder,D., Messing,M., Mueller,F.J., Aboody,K.S., Kim,S.U., Black,P.M., Carroll,R.S., Westphal,M., Lamszus,K. Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche. Brain Research 2009; 1268(-;-):24-37. >>> Vascular endothelial growth factor, recomb. human; CSF/CNS (parenchyma); Mice (nude); 2004; ; Controls received mp w/PBS; animal info (6 wks old).

P9443 Segi-Nishida,E., Warner-Schmidt,J.L., Duman,R.S. Electroconvulsive seizure and VEGF increase the proliferation of neural stem-like cells in rat hippocampus. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2008; 105(-32-):11352-11357. >>> Vascular endothelial growth factor 164, recomb. rat; PBS; CSF/CNS; Rat; 1003D; 3 days; 24 hours; Controls received mp w/ vehicle; brain tissue distribution; peptides; animal info (male, Sprague Dawley, 175-200 g.); delayed delivery (in the 48 hour infusion, PBS infused for 24 hours to "avoid the influence of cannulation and anesthesia." (p. 11354) then VEGF infused for 24 hours).

P9248 Poesen,K., Lambrechts,D., Van Damme,P., Dhondt,J., Bender,F., Frank,N., Bogaert,E., Claes,B., Heylen,L., Verheyen,A., Raes,K., Tjwa,M., Eriksson,U., Shibuya,M., Nuydens,R., Van den Bosch,L., Meert,T., D'Hooge,R., Sendtner,M., Robberecht,W., Carmeliet,P. Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration. Journal of Neuroscience 2008; 28(-42-):10451-10459. >>> Vascular endothelial growth factor-B186, recomb. mouse; CSF, artificial; CSF/CNS; Rat; 2004; 100 days; Controls received mp w/ vehicle; long-term study; pumps replaced every 25 days; no stress (see pg. 10456); stability verified by 4 weeks in mp at 37 degrees Celsius; animal info (HAN-Wistar x Sprague Dawley-hSOD1G93A, 60 days old); behavioral testing (Rotarod test); "this delivery route was chosen because previous studies demonstrated that intracerebroventricularly delivered VEGF diffuses from the CSF into the neural parenchyma, where it reaches it's target motor neurons." (p. 10456).

P9198 Rennel,E.S., Hamdollah-Zadeh,M.A., Wheatley,E.R., Magnussen,A., Schueler,Y., Kelly,S.P., Finucane,C., Ellison,D., Cebe-Suarez,S., Ballmer-Hofer,K., Mather,S., Stewart,L., Bates,D.O., Harper,S.J. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. European Journal of Cancer 2008; 44(-13-):1883-1894. >>> Vascular endothelial growth factor-165-b, recomb.; NaCl, sterile; SC; Mice; 28 days; No stress (see pg. 1888); half-life (p. 1893) 25 min in mice, 13.8-72 min in rats; cancer (colon); post op. care (Temgesic); animal info (C57/Bl6, 720 g.); silk sutures used; "no adverse effects were observed with this infusion of VEGF165b" pg. 1888; compound is an anti angiogenic isoform of VEGF.

P9139 Nicoletti,J.N., Shah,S.K., McCloskey,D.P., Goodman,J.H., Elkady,A., Atassi,H., Hylton,D., Rudge,J.S., Scharfman,H.E., Croll,S.D. Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. Neuroscience 2008; 151(-1-):232-241. >>> Vascular endothelial growth factor, recomb. human; BowAng1; Flt-Fc; CSF/CNS (dorsal hippocampus); Rat; 5 days; Controls received mp w/ PBS; animal info (male, Sprague Dawley, adult, 250-350 g.); cannula, polyvinyl catheter from Plastics One used; BowAng1 is a fusion of four molecules of angiopoietin-1 with two molecules of hFC; Flt-Fc is an immunoadhesin.

P9097 Ohm,J.E., Gabrilovich,D.I., Sempowski,G.D., Kisseleva,E., Parman,K.S., Nadaf,S., Carbone,D.P. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003/6/15; 101(-12-):4878-4886. >>> Vascular endothelial growth factor; SC; Mice (transgenic); 7-28 days; Controls received mp w/ PBS; no stress (see pg. 4880); animal info (female, 6-8 wks old, DO11.10); immunology.

P8833 Boodhwani,M., Voisine,P., Rue,M., Sodha,N.R., Feng,J., Xu,S.H., Bianchi,C., Settke,F.W. Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction. European Journal of Cardio-thoracic Surgery 2008; 33(-4-):645-650. >>> Vascular endothelial growth factor 165, recomb. human; Heparin; Intramyocardial; Pig (miniswine); 2ML4; 4 weeks; Tissue perfusion (myocardial); half-life (p. 649) "short"; cardiovascular; peptides; ischemia (cardiac); animal info (Yucatan mini-swine, 20-30 kg.).

P8799 Tsuchiya,A., Heike,T., Baba,S., Fujino,H., Umeda,K., Matsuda,Y., Nomoto,M., Ichida,T., Aoyagi,Y., Nakahata,T. Sca-1+ endothelial cells (SPECs) reside in the portal area of the liver and contribute to rapid recovery from acute liver disease. Biochemical and Biophysical Research Communications 2008; 365(-3-):595-601. >>> Vascular endothelial growth factor-inhibitor; DMSO; IP; Mice; 9, 11 days; Controls received mp w/ vehicle; animal info (C57BL/6; 4, 8, 12 wks old; anti-Fas Ab-induced liver damage); agent also known as CBO-P11.

P8512 Huang,Y., Chen,X., Dikov,M.M., Novitskiy,S.V., Mosse,C.A., Yang,L., Carbone,D.P. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110(-2-):624-. >>> Vascular endothelial growth factor 165, recomb. human; vascular endothelial growth factor, receptor-2 selective; vascular endothelial growth factor, receptor-1 selective; Mice; 2004; 28 days; Controls received mp w/ PBS; cancer; peptides; animal info (female, Balb/c, 6-8 weeks old); angiogenesis; hematology.

P8366 Dorrell,M.I., Aguilar,E., Scheppke,L., Barnett,F.H., Friedlander,M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-3-):967-972. >>> Vascular endothelial growth factor, aptamer; EMD472523; T2-TrpRS; PBS; CSF/CNS (intratumoral); Rat; 2001D; 2ML2; 2ML4; 3,6 days; 24 hours; Controls received mp w/ vehicle; cancer (gliosarcoma); animal info (male, Fischer, 344); EMD472523 is an integrin antagonist, VEGF aptamer is chemically identical to Macugen; T2 is a proteolytic fragment of tryptophan tRNA synthetase; all agents have angiostatic activity; tissue perfusion (tumor).

P8306 Tiranathanagul,K., Dhawan,V., Lytle,I.F., Zhang,W., Borschel,G.H., Buffington,D.A., Tziampazis,E., Brown,D.L., Humes,H.D. Tissue engineering of an implantable bioartificial hemofilter. ASAIO Journal 2007; 53(-2-):176-186. >>> Platelet-derived growth factor-BB; vascular endothelial growth factor 164; Saline, normal; albumin, rat serum; acetic acid; IA (femoral); IV (femoral); Rat; 2004; 28 days; Artificial kidney; controls received mp w/ vehicle; peptides; animal info (male, Fisher 344); mp attached by cannula to bioartificial hemofilter device, which surrounded and delivered agent to the femoral vessels; nephrology.

P8299 Cruze,C.A., Su,F., Limberg,B.J., Deutsch,A.J., Stoffolano,P.J., Dai,H.J., Buchanan,D.D., Yang,H.T., Terjung,R.L., Spruell,R.D., Mittelstadt,S.W., Rosenbaum,J.S. The Y2 receptor mediates increases in collateral-dependent blood flow in a model of peripheral arterial insufficiency. Peptides 2007; 28(-2-):269-280. >>> Peptide YY, recomb. human; peptide YY (3-36), recomb. human; vascular endothelial growth factor 165; PBS; glycerol; sodium citrate; Tween 20; IA (iliac); Rat; 14 days; Controls received mp w/ vehicle; replacement therapy (femoral artery occlusion); dose-response (fig. 4); half-lfie (p. 276)<30 minutes; cardiovascular; peptides; ischemia (hindlimb); animal info (male, Sprague-Dawley, 325-350 grams).

P8267 Warner-Schmidt,J.L., Duman,R.S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-11-):4647-4652. >>> Vascular endothelial growth Factor 164, recomb. rat; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; peptides; animal info (male, Sprague-Dawley, 175-200g.).

P8196 Heymans,S., Luttun,A., Nuyens,D., Theilmeier,G., Creemers,E., Moons,L., Dyspersin,G.D., Cleutjens,J.P., Shipley,M., Angellilo,A., Levi,M., Nube,O., Baker,A., Keshet,E., Lupu,F., Herbert,J.M., Smits,J.F., Shapiro,S.D., Baes,M., Borgers,M., Collen,D., Daemen,M.J., Carmeliet,P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat.Med. 1999/10; 5(-10-):1135-1142. >>> Vascular endothelial growth factor 165, recomb. human; SC; Mice; 2001; 7 days; Controls received no treatment; cardiovascular; peptides; ischemia (cardiac); animal info (8-12 weeks old); myocardial infarction by coronary artery ligation.

P8163 Boodhwani,M., Mieno,S., Voisine,P., Feng,J., Sodha,N., Li,J., Sellke,F.W. High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. Journal of Thoracic and Cardiovascular Surgery 2006; 132(-6-):1299-1306. >>> Vascular endothelial growth factor 165, recomb. human; Heparin; Perivascular (circumflex coronary artery); Mini-pig; 2ML4; 4 weeks; Cardiovascular; peptides; ischemia (cardiac); animal info (male, female, yucatan, 20-30 kg, 23 weeks old).

P8096 Gosain,A., Matthies,A.M., Dovi,J.V., Barbul,A., Gamelli,R.L., DiPietro,L.A. Exogenous pro-angiogenic stimuli cannot prevent physiologic vessel regression. Journal of Surgical Research 2006; 135(-2-):218-225. >>> Vascular endothelial growth factor 164, recomb.; platelet-dreived growth factor; fibroblast growth factor-2; Wound site; Mice; 2002; 11 days; Controls received mp w/ PBS; functionality of mp verified by VEGF levels in wound sponges, residual volume; stability verified by activity of residual VEGF in endothelial cell cord formation assay (fig.4); cardiovascular; peptides; animal info (female, BALB/c, 8-9 wks old, implanted sponge wounds); "The activity of VEGF isolated from the pump was comparable to fresh recombinant VEGF 164, confriming that the recombinant growth factors present in the mini-osmotic pump retain robust biological activity." (p.221).

P8017 Kawai,T., Takagi,N., Mochizuki,N., Besshoh,S., Sakanishi,K., Nakahara,M., Takeo,S. Inhibitor of vascular endothelial growth factor receptor tyrosine kinase attenuates cellular proliferation and differentiation to mature neurons in the hippocampal dentate gyrus after transient forebrain ischemia in the adult rat. Neuroscience 2006; 141(-3-):1209-1216. >>> Vascular endothelial growth factor receptor tyrosine kinase inhibitor; DMSO; CSF/CNS (dentate gyrus); Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (fig. 4); enzyme inhibitor (VEGF receptor tyrosine kinase); ischemia (transient forebrain); animal info (male, Wistar, 8 weeks old, carotid artery occlusion); 0.5% DMSO; agent also known as 4-[(4'-chloro-2'-fluoro) phenylamino]-6,7-dimethoxyquinazoline; tissue perfusion (dentate gyrus).

P7987 Wang,Y.M., Galvan,V., Gorostiza,O., Ataie,M., Jin,K.L., Greenberg,D.A. Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat. Brain Research 2006; 1115(--):186-193. >>> Vascular endothelial growth factor; CSF, artificial; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; ischemia (cerebral); behavioral study.

P7784 Gaudio,E., Barbaro,B., Alvaro,D., Glaser,S., Francis,H., Ueno,Y., Meininger,C.J., Franchitto,A., Onori,P., Marzioni,M., Taffetani,S., Fava,G., Stoica,G., Venter,J., Reichenbach,R., De Morrow,S., Summers,R., Alpini,G. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 2006; 130(-4-):1270-1282. >>> Vascular endothelial growth factor-A, recomb. mouse; vascular endothelial growth factor-C, recomb. mouse; Saline; BSA; IP; Rat; 1 week; Controls received mp w/ vehicle; peptides; animal info (male, Fischer 344, 150-175g.).

P7731 Carr,A.N., Howard,B.W., Yang,H.T., Eby-Wilkens,E., Loos,P., Varbanov,A., Qu,A., DeMuth,J.P., Davis,M.G., Proia,A., Terjung,R.L., Peters,K.G. Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: Support for an endothelium-dependent mechanism. Cardiovascular Research 2006; 69(-4-):925-935. >>> Vascular endothelial growth factor; stromal cell-derived factor-1a; PBS; glycerol; sodium acetate; sodium azide; IA (iliac); Rat; 2 weeks; Controls received mp w/ vehicle; dose-response (table 1); cardiovascular; peptides; animal info (adult); bilateral femoral artery ligation; occlusive cardiovascular disease.

P7561 Sun,Y.J., Jin,K.L., Childs,J.T., Xie,L., Mao,X.O., Greenberg,D.A. Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: Evidence from knockout mice and growth factor administration. Developmental Biology 2006; 289(-2-):329-335. >>> Vascular endothelial growth factor-B; CSF, artificial; CSF/CNS; Rat; mice; 1003D; 3 days; Controls received mp w/ vehicle; ischemia (cerebral); animal info (mice, 10-12 wk old; male, Sprague-Dawley).

P7495 Burchardt,M., Burchardt,T., Anastasiadis,A.G., Buttyan,R., de la Taille,A., Shabsigh,A., Frank,J., Shabsigh,R. Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis. UROLOGY 2005; 66(-3-):665-670. >>> Vascular endothelial growth factor, human 165; Saline, sterile; heparin; IA (renal); Rat; 2004; 28 days; Controls received mp w/ vehicle; functionality of mp verified by VEGF serum immunoassay; comparison of CDNA plasmid micro-injections vs. mp; gene therapy; peptides; animal info (male, Sprague-Dawley); urology; 2000 Units of heparin used.

P7417 Schmidt,N.O., Przylecki,W., Yang,W., Ziu,M., Teng,Y., Kim,S.U., Black,P.M., Aboody,K.S., Carroll,R.S. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. NEOPLASIA 2005; 7(-6-):623-629. >>> Vascular endothelial growth factor, recomb. human; CSF/CNS (parenchyma); Mice; 2004; ; Controls received mp w/ PBS; functionality of mp verified by residual volume; cancer.

P6908 Alonso,G., Galibert,E., Duvoid-Guillou,A., Vincent,A. Hyperosmotic stimulus induces reversible angiogenesis within the hypothalamic magnocellular nuclei of the adult rat: a potential role for neuronal vascular endothelial growth factor. BMC NEUROSCIENCE 2005; 6(--):U1-U19. >>> Antibody, anti-vascular endothelial growth factor; PBS; CSF/CNS (supraoptic nucleus); Rat; 1007D; 6 days; Schematic fig 9; 10 mm, 26 gauge cannula used.

P6834 Hashiya,N., Jo,N., Aoki,M., Matsumoto,K., Nakamura,T., Sato,Y., Ogata,N., Ogihara,T., Kaneda,Y., Morishita,R. In vivo evidence of angiogenesis induced by transcription factor ets-1 - Ets-1 is located upstream of angiogenesis cascade. Circulation 2004; 109(-24-):3035-3041. >>> Antibody, anti-vascular endothelical growth factor; antibody, immunoglobulin G, rabbit; IP; Mice; ; Cardiovascular; ischemia.

P6730 Storkebaum,E., Lambrechts,D., Dewerchin,M., Moreno-Murciano,M.P., Appelmans,S., Oh,H., Van Damme,P., Rutten,B., Man,W.Y., De Mol,M., Wyns,S., Manka,D., Vermeulen,K., Van den Bosch,L., Mertens,N., Schmitz,C., Robberecht,W., Conway,E.M., Collen,D., Moons,L., Carmeliet,P., Carmeliet,P. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nature Neuroscience 2005; 8(-1-):85-92. >>> Vascular endothelial growth factor, recomb. rat; CSF/CNS; Rat; 2004; 100 days; Long-term study; pumps replaced every 28 days; ALZET brain infusion kit used; VEGF was cleared from CSF within 3h; "70-80% of VEGF in pumps remained active after 4 weeks."; neurodegenerative (Amyotrophic Lateral Sclerosis).

P6715 Ohm,J.E., Shurin,M.R, Esche,C., Lotze,M.T., Carbone,D.P, Gabrilovich,D  The Journal of Immunology 1999; 163(--):3260-3268. >>> Vascular endothelial growth factor; PBS; SC; Mice; 14 days; Controls received mp w/ vehicle; cancer; immunology.

P6634 Croll,S.D., Ransohoff,R.M., Cai,N., Zhang,Q., Martin,F.J., Wei,T., Kasselman,L.J., Kintner,J., Murphy,A.J., Yancopoulos,G.D., Wiegand,S.J. VEGF-mediated inflammation precedes angiogenesis in adult brain. Experimental Neurology 2004; 187(-2-):388-402. >>> Vascular endothelial growth factor 164, mouse; Flt-Fc; angiopoietin I, human; angiopoietin II, human; PBS; CSF/CNS (frontoparietal cortex); Rat; 2002; 1,2,3,4,5,7 days; Controls received mp w/ vehicle or hFc; dose-response (fig. 1); brain tissue distribution; peptides; cyanoacrylate adhesive (Loctite 495).

P6614 Kodama,I., Niida,S., Sanada,M., Yoshiko,Y., Tsuda,M., Maeda,N., Ohama,K. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice. Journal of Bone and Mineral Research 2004; 19(-2-):200-206. >>> Antibody, anti-vascular endothelial growth factor; vascular endothelial growth factor; Flt-1/Fe chimera; SC; Mice; 1002; 2 weeks; Plasma levels taken.

P6564 Suzuki,O., Bishop,A.T., Sunagawa,T., Katsube,K., Friedrich,P.F. VEGF-promoted surgical angiogenesis in necrotic bone. MICROSURGERY 2004; 24(-1-):85-91. >>> Vascular endothelial growth factor 165; Phosphate buffer; albumin rabbit serum; Bone; Rabbit; 1003D; 3 days.

P6459 Ward,W.K., Quinn,M.J., Wood,M.D., Tiekotter,K.L., Pidikiti,S., Gallagher,J.A. Vascularizing the tissue surrounding a model biosensor: how localized is the effect of a subcutaneous infusion of vascular endothelial growth factor (VEGF). BIOSENSORS&BIOELECTRONICS 2003; 19(-3-):155-163. >>> Vascular endothelial growth factor 165; PBS; BSA; SC; Rat; 2004; 28 days; Controls received mp w/ vehicle; no stress (see pg. 157); mp primed 40 hours at 38 degrees Celsius; "the rats tolerated the implants well without distress." (P.157); mp explanted at day 40.

P6370 Manoonkitiwongsa,P.S., Schultz,R.L., McCreery,D.B., Whitter,E.F., Lyden,P.D. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. Journal of Cerebral Blood Flow and Metabolism 2004; 24(-6-):693-702. >>> Vascular endothelial growth factor; Saline; IA (carotid); Rat; 2001; 7 days; Controls received mp w/ vehicle; dose response (p. 697); stroke; ischemia (cerebral); biocompatible glue was used to secure catheter in artery.

P5978 Luttun,A., Tjwa,M., Moons,L., Wu,Y., Angelillo-Scherrer,A., Liao,F., Nagy,J.A., Hooper,A., Priller,J., De Klerck,B., Compernolle,V., Daci,E., Bohlen,P., Dewerchin,M., Herbert,J.M., Fava,R., Matthys,P., Carmeliet,G., Collen,D., Dvorak,H.F., Hicklin,D.J., Carmeliet,P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Medicine 2002; 8(-8-):831-840. >>> Placental growth factor; vascular endothelial growth factor; SC; Mice; 2001; 7 days; Angiogenesis.

P5966 Roguin,A., Avivi,A., Nitecki,S., Rubinstein,I., Levy,N.S., Abassi,Z.A., Resnick,M.B., Lache,O., Melamed-Frank,M., Joel,A., Hoffman,A., Nevo,E., Levy,A.P. Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat Spalax ehrenbergi VEGF. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O F AMERICA 2003; 100(-8-):4644-4648. >>> DNA, naked; vascular endothelial growth factor, DNA; Water; IM; Mice; 2001; 7 days; Controls received mp w/ saline; tissue perfusion (quadriceps muscle); gene therapy; fenestrated catheter; pump implanted IP; "we have shown that when using plamid DNA, continuous administration is superior to multiple simultaneous IM injections." (p. 4647).

P5929 Namba,T., Koike,H., Murakami,K., Aoki,M., Makino,H., Hashiya,N., Ogihara,T., Kaneda,Y., Kohno,M., Morishita,R. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 2003; 108(-18-):2250-2257. >>> Immunoglobulin G; antibody, anti-vascular endothelial growth factor; IP; Rat; 28 days; Cardiovascular; peptides; pump model not stated; ischemia (hind-limb).

P5731 Sun,Y.J., Jin,K.L., Xie,L., Childs,J., Mao,X.O., Logvinova,A., Greenberg,D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. Journal of Clinical Investigation 2003; 111(-12-):1843-1851. >>> Vascular endothelial growth factor; vascular endothelial growth factor R2/FC chimera; Phosphate buffer; BSA; Bone (tibia); Rabbit; 2ML2; 3 days; Controls received mp w/ vehicle; tissue perfusion (osteotomy site); replacement therapy (distraction osteogenesis); stability verified by in vitro assay for 2 weeks at 37 C. (p. 336);.

P5645 Pipp,F., Heil,M., Issbrucker,K., Ziegelhoeffer,T., Martin,S., van den Heuvel,J., Weich,H., Fernandez,B., Golomb,G., Carmeliet,P., Schaper,W., Clauss,M. VEGFR-1-selective VEGF homologue PlGF is arteriogenic - Evidence for a monocyte-mediated mechanism. Circulation Research 2003; 92(-4-):378-385. >>> Vascular endothelial growth factor; Vascular endothelial growth factor-E; Monocyte chemoattractant protein-1; Placental growth factor; Phosphate buffer; albumin; IA (femoral); Mice; rabbit; 1 week; Controls received mp w/ vehicle; dose-response (p.381); peptides; placenta growth factor (PlGF) is a VEGF homologue; VEGF-E is a chimera containing the heparin-binding domain of VEGF; MCP-1.

P5606 Harrigan,M.R., Ennis,S.R., Sullivan,S.E., Keep,R.F. Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume. Acta Neurochirurgica 2003; 145(-1-):49-53. >>> Vascular endothelial growth factor 165; PBS; BSA; CSF/CNS; Rat; 2001; 7 days; Controls received mp/ w vehicle; cardiovascular; peptides; ALZET brain infusion kit used; VEGF was recomb. human; ischemia (cerebral); MCAO.

P5323 Proescholdt,M.A., Jacobson,S., Tresser,N., Oldfield,E.H., Merrill,M.J. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. Journal of Neuropathology and Experimental Neurology 2002; 61(-10-):914-925. >>> Vascular endothelial growth factor; PBS; Albumin, rabbit serum; CSF/CNS (sciatic nerve); Rabbit; 1003D; 12 days; Controls received mp w/ vehicle; tissue perfusion (sciatic nerve graft); peptides; human recomb. VEGF used; transplantation;.

P5197 Masaki,I., Yonemitsu,Y., Yamashita,A., Sata,S., Tanii,M., Komori,K., Nakagawa,K., Hou,X., Nagai,Y., Hasegawa,M., Sugimachi,K., Sueishi,K. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ.Res 2002/5/17; 90(-9-):966-973. >>> Antibody, anti-Vascular Endothelial Growth Factor; Immunoglobulin G; IP; Mice; 1007D; 7 days; Peptides; VEGF levels checked by ELISA; ischemia (limb).

P5132 Yang,R.H., Ogasawara,A.K., Zioncheck,T.F., Ren,Z., He,G.W., DeGuzman,G.G., Pelletier,N., Shen,B.Q., Bunting,S., Jin,H.K. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002; 39(--):815-820. >>> Vascular Endothelial Growth Factor; Saline; IV (jugular); rat; 7 days; controls received mp w/ vehicle; cardiovascular; antihypertensive.

P5053 Harrigan,M.R., Ennis,S.R., Masada,T., Keep,R.F. Intraventricular infusion of vascular endothelial growth factor promotes cerebral angiogenesis with minimal brain edema. Neurosurgery 2002; 50(-3-):589-598. >>> Vascular Endothelial Growth Factor; PBS; Albumin, bovine serum; CSF/CNS; CSF/CNS (cortex); CSF/CNS (third ventricle); rat; 2001; 7 days; controls received mp w/ vehicle; dose response (p. 591); half-life = 6 min. (p. 594); peptides; brain tissue distribution; VEGF was human recombinant; benefits of continuous infusion p. 594.

P5032 Krum,J.M., Mani,N., Rosenstein,J.M. Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain. Neuroscience 2002; 110(-4-):589-604. >>> Vascular endothelial growth factor; PBS; CSF/CNS (striatum); rat; 2001; 1, 3 or 7 days; controls received mp w/ vehicle; comparison of gelfoam sponge administration vs. mp infusion; stress/adverse reaction (p. 592) necrotic tissue or cavity around cannula; peptides; brain tissue distribution, VEGF was recombinant human; some controls received cannulas with no pump attached.

P4874 Masuda,Y., Shimizu,A., Mori,T., Ishiwata,T., Kitamura,H., Ohashi,R., Ishizaki,M., Asano,G., Sugisaki,Y., Yamanaka,N. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. American Journal of Pathology 2001; 159(--):599-608. >>> Vascular endothelial growth factor; Saline; IP; rat; 2ML1; 7 days; controls received mp w/ vehicle; immunology; peptides;.

P4782 Yang,H.T., Yan,Z., Abraham,J.A., Terjung,R.L. VEGF121- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production.. American Journal of Physiology-Heart and Circulatory Physiology 2001; 280(--):H1097-H1104. >>> Vascular endothelial growth factor 121; Fibroblast growth factor, basic;; PBS; Sodium citrate; Glycerol;; IA (femoral);; rat;; 2002;; 14 days;; Controls received mp w/ vehicle; cardiovascular; peptides; vehicle was PBS w/ 10% sodium citrate and 1.6% glycerol; sodium citrate used to prevent coagulation; glycerol used to enhance protein stability;.

P4582 Lindner,V, Reidy,M.A. Expression of VEGF receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to VEGF.. Arterioscler.Thromb.Vasc.Biol. 1996; 16(--):1399-1405. >>> Vascular endothelial growth factor;; Saline;; IV (jugular);; rat;; 2ML2;; 2 weeks;; controls received mp w/vehicle; comparison of bolus injections vs. mp; peptides; recomb. human VEGF used;.

P4465 Gabrilovich,D, Ishida,T, Oyama,T, Ran,S, Kravtsov,V, Nadaf,S, Carbone,D.P  Blood 1998/12/1; 92(-11-):4150-4166. >>> Vascular endothelial growth factor;; PBS;; SC;; mice;; 14, 28 days;; controls received mp w/vehicle; functionality of mp verified by plasma levels; dose-response (p. 4152); immunology; peptides; "Because VEGF has a short in vivo half-life ..., we used an in vivo model utilizing a continuous infusion of VEGF via an osmotic infusion pump" (p. 4159).

P4375 Rosenstein,J.M., Mani,N., Silverman,W.F., Krum,J.M. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc.Natl.Acad.Sci.USA 1998/6; 95(--):7086-7091. >>> Vascular endothelial growth factor;; PBS;; CSF/CNS (cortex);; rat;; 2001;; 7 days;; controls received mp with vehicle; peptides;.

P4345 Proescholdt,M.A., Heiss,J.D., Walbridge,S., Muhlhauser,J., Capogrossi,M.C., Oldfield,E.H., Merrill,M.J. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. Journal of Neuropathology and Experimental Neurology 1999/6; 58(-6-):613-627. >>> Vascular endothelial growth factor; Vitronectin, rat; PBS; Albumin, rat serum; CSF/CNS; Rat; 2001; 6,12 days; Controls received mp with vehicle; immunology; peptides; brain tissue distribution assessed with anti-VEGF antibody immunostaining; recomb. human, carrier-free VEGF 165 used; VEGF infused alone or with rat vitronectin, which is an extracellular matrix protein;.

P4128 Hopkins,S.P., Bulgrin,J.P., Sims,R.L., Bowman,B., Donovan,D.L., Schmidt,S.P. Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischemia. J.Vasc.Surg. 1998; 27(-5-):886-895. >>> Vascular endothelial growth factor; Nitroglycerin; Saline; Heparin; IA (iliac); rabbit; 2ML4; 28 days; pump diagram (p. 888); 22 g intravenous catheter was inserted into tygon tubing; "implantable osmotic pumps offer an alternative simple delivery method, providing a constant release of soluble agents in a steady-state fashion." (p. 892); controls received mp w/vehicle; good methods (pp. 887-888); cardiovascular; peptides; ischemia.

P3458 Lopez,J.J., Simons,M. Local extravascular growth factor delivery in myocardial ischemia. Drug Delivery 1996; 3(--):143-147. >>> Vascular endothelial growth factor; Heparin; Saline, sterile;; perivascular (circumflex artery adventitia); pig; 2ML2; 4 weeks; tissue perfusion (adventitia); peptides; pumps placed inside chest wall; cardiovascular; ischemia (cardiac).

P3411 Harada,K., Friedman,M., Lopez,J.J., Wang,S.Y., Li,J., Prasad,P.V., Pearlman,J.D., Edelman,E.R., Sellke,F.W., Simons,M. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am.J.Physiol.(Heart Circ.Physiol.39) 1996; 270(--):H1791-H1802. >>> Vascular endothelial growth factor; Saline; Heparin; perivascular (circumflex coronary artery); pig; 2ML4; 4 weeks; controls received vehicle infusion; tissue perfusion (adventitia of coronary artery); peptides; ischemia (cardiac); 250 U/ml of heparin.

P3119 Sellke,F.W., Wang,S.Y., Friedman,M., Dai,H.B., Harada,K., Lopez,J.J., Simons,M. B-adrenergic modulation of the collateral-dependent coronary microcirculation. J.Surg.Res. 1995; 59(--):185-190. >>> Vascular endothelial growth factor; Saline; Heparin; perivascular (circumflex coronary artery); pig; 2ML4; no duration posted; controls received occluder&mp with vehicle; peptides; ameroid occluder placed around LCX coronary artery; pump catheter placed distal to this; pump sutured to chest wall; tissue perfusion (perivascular); 25 U/ml of heparin.